Modern medical practice often has to deal with cardiac arrhythmia caused both by a pathologic heart state such as cardial ischemia, tachycardia and by various pharmaceutical prepartions, for example, strophanthin. In these cases preparations are used possesing antiarrhythmic activity, i.e. preparations curing the crdiac arythmia.
Antiarrhythmic activity is known to be displayed by quinidine and novocaine amide (procaine amide) (M.D.Mashkovsky, (Lekarstvennye sredstva" (Medicinal Agents), "Medicine" Publishers, Moscow, v.1, 1977, p.p. 370-372). However, these preparations are toxic and posses insufficient antiarrthythmic activity; cure the arrythmia in certain cases only and, furthermore, they cause some side-effects, e.g. drastically reduce the arterial pressure.
Preparations having pronounced antiarrhythmic activity within a wide range and causing no side-effects are not known in the present-day medical practice.
An object of the present invention is to provide a compound, which would possess a pronounced antiarrhythmic activity, cause no side-effects and be less toxic than the prior-art preparations.